Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Acquisitions (2019)

Historic Acquisitions for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Q1 2019 value amounting to $3.1 million.

  • Lineage Cell Therapeutics' Acquisitions changed N/A to $3.1 million in Q1 2019 from the same period last year, while for Dec 2019 it was $3.1 million, marking a year-over-year change of. This contributed to the annual value of $3.1 million for FY2019, which is N/A changed from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Acquisitions stood at $3.1 million for Q1 2019.
  • Lineage Cell Therapeutics' 5-year Acquisitions high stood at $3.1 million for Q1 2019, and its period low was $3.1 million during Q1 2019.